Enlivex Therapeutics (ENLV) Competitors $0.98 +0.04 (+3.79%) As of 11:00 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. CHRS, PLRX, ENTX, MGNX, XBIT, IZTC, CLLS, TCRX, GNTA, and JMACShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Coherus BioSciences (CHRS), Pliant Therapeutics (PLRX), Entera Bio (ENTX), MacroGenics (MGNX), XBiotech (XBIT), Invizyne Technologies (IZTC), Cellectis (CLLS), TScan Therapeutics (TCRX), Genenta Science (GNTA), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Its Competitors Coherus BioSciences Pliant Therapeutics Entera Bio MacroGenics XBiotech Invizyne Technologies Cellectis TScan Therapeutics Genenta Science Maxpro Capital Acquisition Enlivex Therapeutics (NASDAQ:ENLV) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Which has higher valuation & earnings, ENLV or CHRS? Enlivex Therapeutics has higher earnings, but lower revenue than Coherus BioSciences. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$29.07M-$0.66-1.48Coherus BioSciences$272.25M0.33-$237.89M-$1.13-0.69 Does the MarketBeat Community believe in ENLV or CHRS? Coherus BioSciences received 390 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 81.08% of users gave Enlivex Therapeutics an outperform vote while only 64.94% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformEnlivex TherapeuticsOutperform Votes6081.08% Underperform Votes1418.92%Coherus BioSciencesOutperform Votes45064.94% Underperform Votes24335.06% Do institutionals & insiders have more ownership in ENLV or CHRS? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 8.1% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, ENLV or CHRS? Enlivex Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Is ENLV or CHRS more profitable? Enlivex Therapeutics has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -67.57% -58.45% Coherus BioSciences -0.15%N/A -24.44% Do analysts rate ENLV or CHRS? Enlivex Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 922.81%. Coherus BioSciences has a consensus price target of $4.68, indicating a potential upside of 498.51%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Coherus BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to ENLV or CHRS? In the previous week, Enlivex Therapeutics had 1 more articles in the media than Coherus BioSciences. MarketBeat recorded 4 mentions for Enlivex Therapeutics and 3 mentions for Coherus BioSciences. Coherus BioSciences' average media sentiment score of 0.56 beat Enlivex Therapeutics' score of 0.47 indicating that Coherus BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEnlivex Therapeutics beats Coherus BioSciences on 10 of the 17 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.12M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.008.8527.2320.02Price / SalesN/A256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book0.606.617.124.70Net Income-$29.07M$143.93M$3.23B$247.97M7 Day Performance6.27%3.84%2.74%2.64%1 Month Performance-2.52%11.14%8.94%6.39%1 Year Performance-29.66%4.35%31.59%13.95% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.4753 of 5 stars$0.98+3.8%$10.00+922.8%-33.7%$23.12MN/A-1.0070News CoverageUpcoming EarningsCHRSCoherus BioSciences4.0014 of 5 stars$0.77-1.7%$4.68+511.4%-53.5%$88.81M$272.25M-9.58330PLRXPliant Therapeutics4.3454 of 5 stars$1.44+6.7%$13.31+824.5%-87.1%$88.40M$1.58M-0.4390Positive NewsAnalyst RevisionENTXEntera Bio1.8719 of 5 stars$1.94+5.1%$10.00+415.5%+0.5%$88.18M$223K-7.4620Positive NewsShort Interest ↑MGNXMacroGenics3.827 of 5 stars$1.39+2.2%$5.71+311.1%-65.3%$87.70M$152.43M-0.88430Positive NewsOptions VolumeXBITXBiotech1.1334 of 5 stars$2.86+0.4%N/A-57.4%$87.20M$4.01M-2.65100Positive NewsIZTCInvizyne TechnologiesN/A$13.40-3.6%N/AN/A$83.78MN/A0.00N/ANews CoverageCLLSCellectis3.6262 of 5 stars$1.49+2.1%$7.00+369.8%-43.3%$82.82M$47.63M-1.15290Gap UpTCRXTScan Therapeutics3.9111 of 5 stars$1.46+2.1%$7.80+434.2%-81.2%$82.62M$4.42M-1.38100Positive NewsGap UpGNTAGenenta Science2.7684 of 5 stars$4.49-0.2%$25.00+456.8%+15.8%$82.12MN/A0.007Short Interest ↓JMACMaxpro Capital AcquisitionN/A$6.10-1.9%N/A+2,712.6%$81.91MN/A0.002,021 Related Companies and Tools Related Companies CHRS Competitors PLRX Competitors ENTX Competitors MGNX Competitors XBIT Competitors IZTC Competitors CLLS Competitors TCRX Competitors GNTA Competitors JMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
